Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024

Brochure More information from http://www.researchandmarkets.com/reports/3047307/ Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024 Description: The concept of bispecific antibodies is increasingly gaining traction in the pharma industry owing to several therapeutic advantages and their potential to address challenges known with the monoclonal antibody based therapies. Bispecific antibodies are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes. The resulting antibody has binding affinities for two or three different epitopes concurrently. The market is still in its infancy. With the EMA approval for Removab in 2009 and recent filing for blinatumomab, a great deal of interest has been generated in the bispecific antibody market. The pipeline, which is rich and diverse, has drugs being developed for both oncological and non-oncological indications. These drugs are based on about 50 different technological platforms developed by companies such as Trion Pharma, Amgen, AbbVie, Ablynx, Affimed and MacroGenics amongst others. The platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. Different binding sites can be exploited to produce bispecific systems with different mechanisms, such as the T cell engager system. During the course of our research, we came across 37 molecules currently in different stages of clinical development. Over 75% of these molecules are industry sponsored and we expect around 8-9 of them to be launched by the end of this decade, providing the much needed push to this market. In addition to the clinical pipeline, we have identified over 70 molecules which are currently in preclinical / discovery phase. Technological advancements, especially in the purification of bispecific antibodies will ensure the development of products with improved safety, potency and efficacy profile. As more products move from pipeline to the market, we expect to see an increase in the investment in this area from various quarters. The 2nd edition of the Bispecific Antibody Therapeutics Market, 2014-2024 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. The report covers bispecific antibody drugs currently available in the market as well as in various stages of clinical trials. These drugs are being developed for both oncological as well as non-oncological indications. The report highlights various companies which are active in the market and discusses, in detail, the underlying technologies which form the basis of many of the pipeline drugs. Expecting more FDA and EMA approvals of bispecific antibodies in the coming years, one of the key objectives of this report has been to forecast the bispecific antibody market, currently at a nascent stage, over the course of next ten years. This is done by analysing - Molecules in pipeline and drugs approved for marketing across various geographical regions - Research programs, focused on bispecific antibody therapeutics, of global pharmaceutical companies and recently established start-ups - Technologies to produce bispecific antibodies - Development and sales potential based on target consumer segments, expected pricing and the likely adoption rate of the new drugs, some of which are expected to be used for lifecycle management of existing drugs - Competitive landscape and inherent threats to growth in the short term and long term The report provides short-mid term and long term market forecasts for the period 2014-2019 and 2019-2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The research, analysis and insights presented in this report include the sales of 11 marketed and pipeline bispecific antibodies. Owing to the niche nature of this market, with most products in the pipeline, we have provided three scenarios for our market forecast to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of market evolution. The figures mentioned in this report are in USD, unless otherwise specified.

Contents: 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Immunotherapy: Antibody Ammunitions 3.3. Antibody Based Therapeutics 3.3.1. Twelve of the Approved Antibody Based Therapeutics are Non-Canonical 3.3.2. Dominance of Antibody Based Therapeutics 3.4. Structure of an Antibody 3.5. Monoclonal Antibodies v/s. Bispecific Antibodies 3.6. Bispecific Antibody Formats 3.7. Evolution of Bispecific Antibodies 3.7.1. First Generation Bispecific Antibodies 3.7.1.1. Triomabs: Made Using Hybridomas/ Quadromas 3.7.1.2. Shortcoming of First Generation Bispecific Antibodies 3.7.2. Second Generation Bispecific Antibodies 3.7.2.1. Tandem Single-chain Variable Fragment (scfv) 3.7.2.2. Diabodies 3.7.2.3. Two-in-one antibody 3.7.2.4. Dual Variable Domain Antibodies (DVD-Ig) 3.7.2.5. Shortcoming of Recombinant Bispecific Antibodies 3.8. Types of Bispecific Antibodies by Mode of Action 3.8.1. T Cell Engagement 3.8.2. Pre-targeting Systems 3.8.3. Ligand Neutralisation and Cross Linking of Receptors System 3.9. Companies Active in the Market 4. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4.1. Introduction 4.2. Drugs Indicated for Oncological Diseases 4.3. Drugs Indicated For Non-Oncological Diseases 4.4. Drugs in Preclinical Trials 4.5. Pipeline Analysis 4.5.1. Drugs are Well Distributed in Phase I and Phase II of Clinical Trials 4.5.2. Mechanism Using CD3 Antigen Recognition 4.5.3. Pipeline Dominated by Drugs Indicated for Oncological Diseases 4.5.4. Companies with the Most Active Pipeline 5. CURRENT MARKET AND FORECAST 5.1. Introduction 5.1.1. Scope and Limitations 5.1.2. Assumptions for Market Forecast 5.2. Overall Bispecific Antibodies Market 5.2.1. Overall Bispecific Antibodies Market Forecast: Short-Midterm, 2014-2019 5.2.2. Overall Bispecific Antibodies Market Forecast: Long Term, 2019-2024 5.3. Evolution of the Bispecific Antibody Market: 2014, 2019 and 2024 5.4. Catumaxomab / Removab (Neovii Biotech) 5.4.1. Drug Specifications 5.4.2. Structure and Mechanism of Action 5.4.3. Orphan Drug Designations 5.4.4. Geographical Presence 5.4.5. Cost 5.4.6. Manufacturing 5.4.7. Current Status of Development 5.4.8. Historical Sales (2011 - Q1 2013) 5.4.9. Reimbursement 5.4.10. Market Opportunity in Cancer Associated Malignant Ascites 5.4.11. Catumaxomab / RemovabSales Forecast: Short-Mid Term, 2014-2019

5.4.12. Catumaxomab / RemovabSales Forecast: Long Term, 2019-2024 5.5. Blinatumomab / MT 103/ MEDI 538 / AMG 103 (Amgen / Astellas Pharma) 5.5.1. Drug Specifications 5.5.2. Mechanism of Action 5.5.3. Amgen Driving Further Development 5.5.4. Orphan Drug Designation 5.5.5. Current Development Status 5.5.6. Key Clinical Trial Results 5.5.7. Competitive Landscape 5.5.8. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Short-Mid Term, 2014-2019 5.5.9. Blinatumomab / MT 103/ MEDI 538 / AMG 103 Sales Forecast: Long Term, 2019-2024 5.6. SAR156597 (Sanofi) 5.6.1. Drug Specifications 5.6.2. Mechanism of Action 5.6.3. Orphan Drug Status 5.6.4. Idiopathic Pulmonary Fibrosis: An Attractive Opportunity 5.6.5. Current Status of Development 5.6.6. SAR156597 Sales Forecast: Short-Mid Term, 2014-2019 5.6.7. SAR156597 Sales Forecast: Long Term, 2019-2024 5.7. MM-111 (Merrimack Pharmaceuticals) 5.7.1. Drug Specifications 5.7.2. Mechanism of Action 5.7.3. Orphan Drug Designation 5.7.4. Manufacturing 5.7.5. Current Development Status 5.7.6. Key Clinical Trial Results 5.7.7. Companion Diagnostic Under Development 5.7.8. MM-111 Sales Forecast: Short-Mid Term, 2014-2019 5.7.9. MM-111 Sales Forecast: Long Term, 2019-2024 5.8. ACE910 / RG6013 (Chugai, Roche) 5.8.1. Drug Specifications 5.8.2. Mechanism of Action 5.8.3. Current Development Status 5.8.4. Competiton for ACE910 5.8.5. ACE910 / RG6013 Sales Forecast: Short-Mid Term, 2014-2019 5.8.6. ACE910 / RG6013 Sales Forecast: Long Term, 2019 2024 5.9. Duligotumab / MEHD7945A / RG7597 (Roche / Genentech) 5.9.1. Drug Specifications 5.9.2. Structure and Mechanism of Action 5.9.3. Current Status of Development 5.9.4. Key Clinical Trial Results 5.9.5. Competition for Duligotumab 5.9.6. Duligotumab/MEHD7945A / RG7597Sales Forecast: Long Term, 2019-2024 5.10. ABT-981 (AbbVie) 5.10.1. Drug Specifications 5.10.2. Mechanism of Action 5.10.3. Current Development Status 5.10.4. Key Clinical Trial Results 5.10.5. Competiton for ABT-981 5.10.6. ABT-981 Sales Forecast: Long Term, 2019 2024 5.11. ABT-122 (AbbVie) 5.11.1. Drug Specifications 5.11.2. Mechanism of Action 5.11.3. Current Development Status 5.11.4. Competition for ABT-122 5.11.5. ABT-122 Sales Forecast: Long Term, 2019-2024 5.12. RG7221/ RO5520985 (Roche) 5.12.1. Drug Specifications 5.12.2. Mechanism of Action 5.12.3. Current Development Status 5.12.4. Competition for RG7221 5.12.5. RG7221 / RO5520985 Sales Forecast: Long Term, 2019 2024 5.13. ALX-0061 (Ablynx)

5.13.1. Drug Specifications 5.13.2. Mechanism of Action 5.13.3. Desirable Features of ALX-0061 5.13.4. Current Status of Development 5.13.5. Key Clinical Trial Results 5.13.6. Competiton for ALX-0061 5.13.7. Collaboration with AbbVie 5.13.8. ALX-0061 Sales Forecast: Long Term, 2019-2024 5.14. Ozoralizumab / ATN-103 (Ablynx) 5.14.1. Drug Specifications 5.14.2. Mechanism of Action 5.14.3. Highs and Lows of Development 5.14.4. CurrentStatus of Development 5.14.5. Key Clinical Trial Results 5.14.6. Competition for Ozoralizumab 5.14.7. Ozoralizumab / ATN-103 Sales Forecast: Long Term, 2019-2024 5.15. Profiles of Some Other Pipeline Drugs 5.15.1. AFM 13 (Affimed) Phase II Planned 5.15.1.1. Drug Specifications 5.15.1.2. Mechanism of Action 5.15.1.3. Co-funding Agreement with the Leukemia and Lymphoma Society 5.15.1.4. Current Development Status and Future Plans 5.15.1.5. Competiton for AFM13 5.15.2. CD20Bi / FBT-A05 / Lymphomun (Fresenius Biotech) investigator-sponsored trials 5.15.2.1. Drug Specifications and Mechanism of Action 5.15.2.2. Current Development Status 5.15.3. TF2 (Immunomedics) pretargeting imaging and radioimmunotherapy agent 5.15.3.1. Drug Specifications 5.15.3.2. Mechanism of Action 5.15.3.3. Current Development Status 5.15.4. Ertumaxomab/Rexomun (Fresenius Biotech) investigator-sponsored trials 5.15.4.1. Drug Specifications 5.15.4.2. Current Development Status 6. TECHNOLOGY PLATFORMS 6.1. Introduction 6.2. Bispecific Antibody Production: Technology Providers and Available Technologies 6.3. Promising Technologies 6.3.1. Triomab / Quadroma (Trion Pharma) 6.3.1.1. The Technology 6.3.1.2. Drugs Based on Triomab 6.3.1.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.2. Tribody Technology (Biotecnol) 6.3.2.1. The Technology 6.3.2.2. Drugs Based on Tribody 6.3.2.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.2.4. Advantages of Tribody Technology 6.3.3. Bispecific T Cell Engager / BiTE (Amgen) 6.3.3.1. The Technology 6.3.3.2. Drugs Based on BiTE 6.3.3.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.3.4. Advantages of BiTE Technology 6.3.4. DART (MacroGenics) 6.3.4.1. The Technology 6.3.4.2. Drugs Based on DART 6.3.4.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.4.4. Advantages of DART 6.3.5. DuoBody (Genmab) 6.3.5.1. The Technology 6.3.5.2. Drugs Based on DuoBody 6.3.5.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.5.4. Advantages of DuoBody Technology 6.3.6. TandAb (Affimed)

6.3.6.1. The Technology 6.3.6.2. Drugs Based on TandAb 6.3.6.3. Advantages of TandAb Technology 6.3.7. DVD-Ig (AbbVie) 6.3.7.1. The Technology 6.3.7.2. Drugs Based on DVD-Ig 6.3.7.3. Advantages of DVD-Ig Technology 6.3.8. Nanobody (Ablynx) 6.3.8.1. The Technology 6.3.8.2. Drugs Based on Nanobody 6.3.8.3. Pharmaceutical Companies Showing Interest in the Technology 6.3.8.4. Advantages of Nanobody 6.3.9. CrossMab Technology (Roche) 6.3.9.1. The Technology 6.3.9.2. Drugs Based on CrossMab 6.3.9.3. Advantages of CrossMab 6.3.10. Dock and Lock (Immunomedics) 6.3.10.1. The Technology 6.3.10.2. Drugs Based on DNL 6.3.10.3. Advantages of DNL Technology 7. PARTNERSHIPS: BACKBONE OF THE GROWING BISPECIFIC INDUSTRY 7.1. Chapter Overview 7.2. Recent Partnerships 7.2.1. Partnership Models 7.2.2. Collaborations Amongst Stakeholders are on a Rise 7.2.3. Product Development Model is the Preferred Mode of Collaboration 7.2.4. Most Active Companies 8. PROFILES OF LEADING COMPANIES 8.1. Chapter Overview 8.2. AbbVie 8.2.1. Overview 8.2.2. Financial Performance 8.2.3. Technology and PipelineDrugs 8.2.3.1. DVD-Ig: The Proprietary Technology 8.2.3.2. Pipeline Drugs 8.2.4. Other Information 8.3. Ablynx 8.3.1. Overview 8.3.2. Financial Performance 8.3.3. Funding 8.3.4. Technology and Pipeline Drugs 8.3.4.1. Nanobody: The Proprietary Technology 8.3.4.2. Pipeline Drugs 8.3.5. Other Information 8.4. Affimed 8.4.1. Overview 8.4.2. Funding 8.4.3. Technology and Pipeline Drugs 8.4.3.1. TandAb Technology 8.4.3.2. Pipeline Drugs 8.4.4. Other Information 8.5. Amgen 8.5.1. Overview 8.5.2. Financial Performance 8.5.3. Technology and Pipeline Drugs 8.5.3.1. BiTE: The Proprietary Technology 8.5.3.2. Pipeline Drugs 8.5.4. Other Information 8.6. Immunomedics 8.6.1. Overview 8.6.2. Financial Performance

8.6.3. Technology and Pipeline Drugs 8.6.3.1. DOCK-AND-LOCK (DNL): The Proprietary Technology 8.6.3.2. Pipeline Drugs 8.7. Merrimack Pharmaceuticals 8.7.1. Overview 8.7.2. Financial Performance 8.7.3. Technology and Pipeline Drugs 8.7.4. Other Information 8.8. Merus 8.8.1. Overview 8.8.2. Funding 8.8.3. Technology and Pipeline Drugs 8.8.3.1. Biclonics: The Proprietary Technology 8.8.3.2. Pipeline Drugs 8.8.4. Other Information 8.9. Neovii Biotech 8.9.1. Overview 8.9.2. Financial Performance 8.9.3. Technologyand Pipeline Drugs 8.9.3.1. Removab: The only Marketed Bispecific Antibody 8.9.4. Other Information 8.10. Roche 8.10.1. Overview 8.10.2. Financial Performance 8.10.3. Technology and Pipeline Drugs 8.10.3.1. The Proprietary Technologies 8.10.3.2. Pipeline Drugs 8.10.3.3. Other Information 8.11. Sanofi 8.11.1. Overview 8.11.2. Financial Performance 8.11.3. Technology and Pipeline Drugs 8.11.3.1. TBTI (tetravalent bispecific tandem Ig): The Proprietary Technology 8.11.3.2. Pipeline Drugs 8.12. Brief Company Profiles 8.12.1. Baliopharm 8.12.2. Bayer 8.12.3. Biotecnol 8.12.4. GSK 8.12.5. MacroGenics 8.12.6. NovImmune 8.12.7. Numab 8.12.8. Paktis Antibody Services GmbH 8.12.9. PharmAbcine 8.12.10. Sorrento Therapeutics 8.12.11. Synimmune 8.12.12. Xencor 8.12.13. Zyngenia 9. SWOT ANALYSIS 9.1. Overview 9.2. Strengths 9.3. Weaknesses 9.4. Opportunities 9.5. Threats 10. INTERVIEW TRANSCRIPTS 11. CONCLUSIONS 11.1. A Budding Market Ready to Bloom 11.2. With Several Advantages, Bispecific Antibodies are likely to Step Shead of Competition 11.3. Improvements in Purification Systems of Bispecific Antibodies is Critical 11.4. Concluding Remarks

12. APPENDIX 1: LIST OF COMPANIES AND ORGANISATIONS 13. APPENDIX 2: TABULATED DATA List of Tables: Table 3.1 Approved Antibody Based Therapeutics Table 4.1 List of Bispecific Antibodies: Clinical Trials (Oncology) Table 4.2 List of Bispecific Antibodies: Clinical Trials (Non-Oncology) Table 4.3 List of Bispecific Antibodies: Preclinical / Discovery Table 5.1 Bispecific Antibodies in Clinical Development (Phase II and Higher): Current Development Phase and Expected Launch Year Table 5.2 Removab: Orphan Drug Designations Table 5.3 Removab: Treatment Schedule and Cost Table 5.4 Removab: Ongoing Clinical Trials Table 5.5 Blinatumomab: Orphan Drug Designations Table 5.6 Blinatumomab / MT 103/ MEDI 538 / AMG 103: Ongoing Clinical Trials Table 5.7 Comparison of the Marketed Targeted Inhibitors for ALL Table 5.8 Comparison of Blinatumomab / MT 103/ MEDI 538 / AMG 103 and SAR3419 Table 5.9 Drugs under Development for Idiopathic Pulmonary Fibrosis, 2014 Table 5.10 SAR156597: Ongoing Clinical Trials Table 5.11 MM-111: Ongoing Clinical Trials Table 5.12 ACE910: Ongoing Clinical Trials Table 5.13 Duligotumab / MEHD7945A / RG7597: Ongoing Clinical Trials Table 5.14 Duligotumab / MEHD7945A / RG7597: Competitor Drug Analysis Table 5.15 ABT-981: Ongoing Clinical Trials Table 5.16 ABT-122: Ongoing Clinical Trials Table 5.17 RG7221: Ongoing Clinical Trials Table 5.18 ALX-0061: Ongoing Clinical Trials Table 5.19 ALX-0061: Competitor Drug Analysis Table 5.20 Ozoralizumab / ATN-103: Ongoing Clinical Trials Table 5.21 Comparison of Leading Anti-Rheumatic Drugs Table 5.22 AFM13: Ongoing Clinical Trials Table 5.23 Comparison of Adcetris with AFM 13 Table 5.24 CD20Bi: Ongoing Clinical Trials Table 5.25 TF2: Ongoing Clinical Trials Table 5.26 Rexomun: Ongoing Clinical Trials Table 6.1 Bispecific Antibodies: List of Technology Platforms Table 6.2 Drugs Based on Triomab Technology Table 6.3 Drugs Based on Tribody Technology Table 6.4 Drugs Based on BiTE Technology Table 6.5 Drugs Based on DART Table 6.6 Drugs Based on TandAb Technology Table 6.7 Drugs Based on DVD-Ig Technology Table 6.8 Drugs Based on Nanobody Technology Table 6.9 Drugs Based on CrossMab Technology Table 6.10 Drugs Based on Dock and Lock Technology Table 7.1 List of Partnerships, 2000-2014 Table 8.1 AbbVie: Pipeline of Bispecific Antibodies Table 8.2 Ablynx: Pipeline of Bispecific Antibodies Table 8.3 Affimed: Pipeline of Bispecific Antibodies Table 8.4 Amgen: Pipeline of Bispecific Antibodies Table 8.5 Immunomedics: Pipeline of Bispecific Antibodies Table 8.6 Merrimack Pharmaceuticals: Pipeline of Bispecific Antibodies Table 8.7 Merus: Pipeline of Bispecific Antibodies Table 8.8 Neovii Biotech: Pipeline of Bispecific Antibodies Table 8.9 Roche: Pipeline of Bispecific Antibodies Table 8.10 Sanofi: Pipeline of Bispecific Antibodies Table 8.11 Baliopharm: Pipeline of Bispecific Antibodies Table 8.12 Bayer: Pipeline of Bispecific Antibodies Table 8.13 Biotecnol: Pipeline of Bispecific Antibodies Table 8.14 GSK: Pipeline of Bispecific Antibodies Table 8.15 MacroGenics: Pipeline of Bispecific Antibodies

Table 8.16 NovImmune: Pipeline of Bispecific Antibodies Table 8.17 Numab: Pipeline of Bispecific Antibodies Table 8.18 PharmAbcine: Pipeline of Bispecific Antibodies Table 8.19 Sorrento Therapeutics: Pipeline of Bispecific Antibodies Table 8.20 Synimmune: Pipeline of Bispecific Antibodies Table 8.21 Xencor: Pipeline of Bispecific Antibodies Table 8.22 Zyngenia: Pipeline of Bispecific Antibodies Table 9.1 SWOT Analysis Table 9.2 Contract Manufacturing Organisations with Bispecific Antibody Capabilities Screening, Expression or Purification Table 9.3 Companies Working to Develop IgG/Non-IgG Fusion Therapeutics Table 13.1 Approved Non-Canonical Antibody Based Therapeutics Table 13.2 Sales (USD BN) of Top 10 drugs, 2013 Table 13.3 Industry Sponsored Pipeline Drugs: By Phase of Development Table 13.4 Industry Sponsored Pipeline Drugs: By Type of Bispecific System Table 13.5 Industry Sponsored Pipeline Drugs: By Indication Table 13.6 Industry Sponsored Oncology Bispecific Drugs: By Type of Cancer Table 13.7 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014-2019 (Base Table 13.8 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014-2019 (Conservative Table 13.9 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014-2019 (Optimistic Table 13.10 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.11 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.12 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.13 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Table 13.14 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Conservative Table 13.15 Catumaxomab/Removab Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Optimistic Table 13.16 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.17 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.18 Catumaxomab/Removab Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.19 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Table 13.20 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Conservative Table 13.21 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Optimistic Table 13.22 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.23 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.24 Blinatumomab / MT 103/ MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.25 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Table 13.26 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Conservative Table 13.27 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Optimistic Table 13.28 SAR156597 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.29 SAR156597 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.30 SAR156597 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.31 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Table 13.32 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Conservative Table 13.33 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Optimistic Table 13.34 MM-111 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.35 MM-111 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.36 MM-111 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic

Table 13.37 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Table 13.38 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Conservative Table 13.39 ACE910 / RG6013 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Optimistic Table 13.40 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.41 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.42 ACE910 / RG6013 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.43 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.44 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.45 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.46 ABT-981 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.47 ABT-981 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.48 ABT-981 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.49 ABT-122 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.50 ABT-122 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.51 ABT-122 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.52 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.53 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.54 RG7221 / RO5520985 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.55 ALX-0061 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.56 ALX-0061 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.57 ALX-0061 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.58 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019-2024 (Base Table 13.59 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019-2024 (Conservative Table 13.60 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019-2024 (Optimistic Table 13.61 AbbVie: Financial Performance, 2012-Q2 2014 (USD BN) Table 13.62 Amgen: Financial Performance, 2012-Q3 2014 (USD BN) Table 13.63 Immunomedics: Financial Performance, 2012-2014 (USD MM) Table 13.64 Merrimack: Financial Performance, 2012- Q2 2014 (USD MM) Table 13.65 Roche: Financial Performance, 2012-Q3 2014 (CHF BN) Table 13.66 Sanofi: Financial Performance, 2012-Q3 2014 (EUR BN) List of Figures: Figure 2.1 Bispecific Antibody Therapeutics: Market Map Figure 3.1 Number of Approved Non-Canonical Antibody Based Therapeutics Figure 3.2 Sales of Top 10 Drugs (USD BN), 2013 Figure 3.3 Parts of an Antibody Figure 4.1 Pipeline Drugs: By Phase of Development Figure 4.2 Pipeline Drugs: By Type of Bispecific System Figure 4.3 Pipeline Drugs: By Indication Figure 4.4 Oncology Bispecific Drugs: By Types of Cancer Figure 5.1 Overall Bispecific Antibodies Market (USD MM), Short-Midterm Forecast: 2014-2019 (Base Figure 5.2 Overall Bispecific Antibodies Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.3 Evolution of Bispecific Antibodies Market: 2014, 2019 and 2024 (Base Figure 5.4 Removab Quarterly Sales, 2011-2013 (EUR MM) Figure 5.5 Malignant Ascites Market Share (%): Distribution by Type of Cancer Figure 5.6 Catumaxomab / Removab Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Figure 5.7 Catumaxomab / Removab Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.8 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Figure 5.9 Blinatumomab / MT 103 / MEDI 538 / AMG 103 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.10 SAR156597 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base Figure 5.11 SAR156597 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.12 MM-111 Market (USD MM), Short-Mid Term Forecast: 2014-2019 (Base

Figure 5.13 MM-111 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.14 ACE910/ RG6013 Market (USD MM), Short-MId Term Forecast: 2014-2019 (Base Figure 5.15 ACE910/ RG6013 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.16 Duligotumab / MEHD7945A / RG7597 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.17 ABT-981 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.18 ABT-122 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.19 RG7221/ RO5520985 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.20 ALX-0061 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 5.21 Sales of Leading Anti-rheumatics Drugs, 2013(USD BN) Figure 5.22 Ozoralizumab / ATN-103 Market (USD MM), Long Term Forecast: 2019-2024 (Base Figure 7.1 Bispecific Antibody Partnerships by Year, Pre 2009-2014 Figure 7.2 Bispecific Antibody Partnerships: Distribution by Type of Partnership Figure 7.3 Bispecific Antibodies Partnerships: Major Stakeholders Figure 8.1 AbbVie: Financial Performance, 2012 Q2 2014 (USD BN) Figure 8.2 Amgen: Financial Performance, 2012 Q3 2014 (USD BN) Figure 8.3 Immunomedics: Financial Performance, 2012-2014 (USD MM) Figure 8.4 Merrimack: Financial Performance, 2012- Q2 2014 (USD MM) Figure 8.5 Roche: Financial Performance, 2012 Q3 2014 (CHF BN) Figure 8.6 Sanofi: Financial Performance, 2012 Q3 2014 (EUR BN) Figure 11.1 Bispecific Antibodies Market Forecast (USD MM): 2014, 2019, 2024 Ordering: Order Online - http://www.researchandmarkets.com/reports/3047307/ Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/ Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Bispecific Antibody Therapeutics Market (2nd Edition), 2014-2024 Web Address: Office Code: Product Formats Please select the product formats and quantity you require: http://www.researchandmarkets.com/reports/3047307/ SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 1899 USD 3999 USD 6499 Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Email Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)

Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number 833 130 83 Sort code 98-53-30 Swift code IBAN number Bank Address ULSBIE2D IE78ULSB98533083313083 Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646) 607-1907 or (646) 964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World